These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6177009)

  • 21. Sensitive method for the determination of 6-oxo-prostaglandin F1 alpha by gas chromatography with electron-capture and mass-fragmentographic detection.
    Tomori E; Cseh G; Vargek M
    J Chromatogr; 1986 Sep; 365():161-9. PubMed ID: 3771702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Significance of the PSA-concentration for the detection of prostate cancer].
    Stachon A
    Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Early detection of prostatic carcinoma: Is PSA screening suitable?].
    Kaulen H
    Dtsch Med Wochenschr; 2003 May; 128(18):977. PubMed ID: 12755136
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of radioimmunoassay and high-resolution gas chromatography mass spectrometry for the quantitative determination of serum thromboxane B2 and 6-keto-PGF1 alpha after pharmacological blockade of thromboxane synthetase.
    Chiabrando C; Castagnoli MN; Noseda A; Fanelli R; Rajtar G; Cerletti C; de Gaetano G
    Prostaglandins Leukot Med; 1984 Oct; 16(1):79-88. PubMed ID: 6440153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased plasma levels of 6-oxo-prostaglandin F1 alpha, a stable metabolite of prostacyclin, in acute kidney transplant rejection.
    Leithner C; Sinzinger H; Peskar BA
    Prostaglandins Med; 1981 Jul; 7(1):15-8. PubMed ID: 7025069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous determination of 6-oxo-prostaglandin F1 alpha and 2,3-dinor-6-oxo-prostaglandin F1 alpha in biological fluids by stable isotope dilution and negative ion chemical ionization mass spectrometry.
    Fischer C; Meese CO
    Biomed Mass Spectrom; 1985 Aug; 12(8):399-404. PubMed ID: 2931130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of vasoactive peptides on prostacyclin synthesis in man.
    Barrow SE; Dollery CT; Heavey DJ; Hickling NE; Ritter JM; Vial J
    Br J Pharmacol; 1986 Jan; 87(1):243-7. PubMed ID: 3513880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simplified assay for the quantification of 2,3-dinor-6-keto-prostaglandin F1 alpha by gas chromatography-mass spectrometry.
    Daniel VC; Minton TA; Brown NJ; Nadeau JH; Morrow JD
    J Chromatogr B Biomed Appl; 1994 Mar; 653(2):117-22. PubMed ID: 8205238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained, substantially increased concentration of prostate-specific antigen in the absence of prostatic malignant disease: an unusual clinical scenario.
    Glenski WJ; Malek RS; Myrtle JF; Oesterling JE
    Mayo Clin Proc; 1992 Mar; 67(3):249-52. PubMed ID: 1372057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostatic specific antigen (PSA).
    Alberti C
    Minerva Urol Nefrol; 1993 Jun; 45(2):83-4. PubMed ID: 7694380
    [No Abstract]   [Full Text] [Related]  

  • 31. Determination of 6-keto-PGF1 alpha, TXB2, PGF2 alpha, PGE2, PGD2 in human blood: a comparison of RIA and GC-NICI-MS.
    Weber C; Beetens J; van de Wiele R; Beile A; Lohkamp R; de Clerck F; Höller M
    Prog Clin Biol Res; 1989; 301():113-7. PubMed ID: 2798442
    [No Abstract]   [Full Text] [Related]  

  • 32. Simultaneous determination of the primary prostanoids prostaglandin E2, prostaglandin F2 alpha and 6-oxoprostaglandin F1 alpha by immunoaffinity chromatography in combination with negative ion chemical ionization gas chromatography-tandem mass spectrometry.
    Mackert G; Reinke M; Schweer H; Seyberth HW
    J Chromatogr; 1989 Sep; 494():13-22. PubMed ID: 2685002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PSA scores: should we use a lower threshold?
    Carter HB
    Johns Hopkins Med Lett Health After 50; 2004 Oct; 17(8):6. PubMed ID: 15602780
    [No Abstract]   [Full Text] [Related]  

  • 34. Prostate-specific antigen (protein and mRNA) analysis in the differential diagnosis and staging of prostate cancer.
    Castaldo G; Cecere G; di Fusco V; Prezioso D; d'Armiento M; Salvatore F
    Clin Chim Acta; 1997 Sep; 265(1):65-76. PubMed ID: 9352130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a radioimmunoassay for the measurement of prostacyclin metabolites in unextracted plasma.
    McLaren M; Belch JJ; Forbes CD
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():41-2. PubMed ID: 3159227
    [No Abstract]   [Full Text] [Related]  

  • 36. Facile method for preparation of 2,3-dinor-6-keto PGF1 alpha, the major urinary metabolite of prostacyclin.
    Balazy M; Brass EP; Gerber JG; Nies AS
    Prostaglandins; 1988 Oct; 36(4):421-30. PubMed ID: 3070630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostacyclin in the circulation of patients with vascular disorders undergoing surgery.
    Ritter JM; Hamilton G; Barrow SE; Heavey DJ; Hickling NE; Taylor KM; Hobbs KE; Dollery CT
    Clin Sci (Lond); 1986 Dec; 71(6):743-7. PubMed ID: 3539459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the eicosapentaenoic acid (EPA) metabolite delta 17-6-keto-PGF1 alpha in human plasma by GC/SIM using [18O] delta 17-6-keto-PGF1 alpha.
    Mizugaki M; Nishikawa M; Hishinuma T; Ohyama Y; Ishibashi M
    Prostaglandins; 1992 Oct; 44(4):317-27. PubMed ID: 1438883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer.
    Jung K; Laube C; Lein M; Türk I; Lichtinghagen R; Rudolph B; Schnorr D; Loening SA
    Int J Cancer; 1998 Oct; 78(3):392-3. PubMed ID: 9766579
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cancer of the prostate detected in the adenomectomy specimen].
    Revol M; Delannoy P; Faure G
    J Urol Nephrol (Paris); 1974; 80(10-11):939-41. PubMed ID: 4142050
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.